title: Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
abstract: BACKGROUND
  Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis. The recommended treatment for this disease includes measures that target obesity and insulin resistance. The present review summarizes the role of newer anti-diabetic agents in treatment of NAFLD.
  
  
  METHODS
  PubMed, MEDLINE and Ovid databases were searched to identify human studies between January 1990 and January 2013 using specified key words. Original studies that enrolled patients with a diagnosis of NAFLD or NASH and involved use of newer classes of anti-diabetic agents for a duration of at least 3 months were included.
  
  
  RESULTS
  Out of the screened articles, four met eligibility criteria and were included in our review. The classes of newer anti-diabetic medications described were dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 analogues.
  
  
  CONCLUSIONS
  Liraglutide and Exenatide showed improvement in transaminases as well as histology in patients with NASH. Sitagliptin showed improvement in transaminases but limited studies are there to access its effect on histology. Further studies are needed to support use of newer anti-diabetic medications in patients with NAFLD.
authors: Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center/New York Presbyterian Healthcare System, Brooklyn, New York, USA; Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, USA. sdsinghal@gmail.com.
authors: Manhal
authors: M
authors: Olaywi
authors: Taruna
authors: T
authors: Bhatia
authors: Sury
authors: S
authors: Anand
authors: Shashideep
authors: S
authors: Singhal
mesh_terms: D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000077270:Exenatide; D005234:Fatty Liver / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D008099:Liver / Q000201:enzymology / Q000473:pathology; D065626:Non-alcoholic Fatty Liver Disease; D010455:Peptides / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D000637:Transaminases / Q000378:metabolism; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; D000637:Transaminases; D000068900:Sitagliptin Phosphate